Inovio Prices $75M Offering at $1.05, a 15% Discount to Thursday's Close
INO has more than doubled off its 52-week low of $0.563.
Summary
Inovio priced an underwritten public offering of 58,747,235 shares at $1.05 each, raising roughly $75 million before fees, with all securities in the offering being sold by Inovio and the offering expected to close on or about Nov. 9. That price is about 15% below the $1.2294 last sale, so buyers are getting a steep discount and existing holders absorb meaningful dilution at a company with a market cap near $150 million. The raise follows yesterday's preliminary prospectus and 8-K disclosing about $48.4 million of quarter-end cash, and it comes just days after the FDA granted accelerated approval to VOCERYQ (INO-3107), Inovio's first approved product. The cash buys runway past the late-Q1 2027 going-concern horizon flagged in the Q2 10-Q, but the launch of VOCERYQ still has to be funded.
At the time of this announcement, INO was trading at $1.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $149.9M. The 52-week trading range was $0.56 to $2.72. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.